The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist (VC) companies increased investments from 2,200 in 2016 to 3,100 in 2021 in biotechnology (biotech) startups.
These startups have advanced medicine overall, improving cell therapy, tissue regeneration, genetic medicine, and more. With increasing innovation, we see an ongoing cycle. VC companies will continue to invest by providing resources and funding for these companies. The future of this industry is set for long-term growth.
This post appeared first on InvestorPlace.